Researchers created fusion proteins combining porcine interferon alpha-1 with thymosin alpha-1 using different connecting linkers and expressed them in bacteria. The fusion proteins retained both antiviral interferon activity and immune-stimulating thymosin activity in lab tests, with different linker designs favoring one activity over the other, demonstrating the feasibility of combining these two immune molecules into a single therapeutic agent.
Wang, Nan; Liu, Songcai; Shi, Hui; Zhang, Peng; Cheng, Yunyun; Su, Dan; Lu, Chao; Yu, Hao; Hao, Linlin